Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Oral Fluconazole Step Down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Oral Fluconazole Step Down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2018

At a glance

  • Drugs Rezafungin (Primary) ; Caspofungin; Fluconazole
  • Indications Candidaemia; Candidiasis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ReSTORE
  • Sponsors Cidara Therapeutics
  • Most Recent Events

    • 01 Oct 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Sep 2018 to 1 Oct 2018.
    • 28 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 27 Sep 2018 According to a Cidara Therapeutics media release, first trial site has been activated for this study. This trial will enrol approximately 184 modified intent-to-treat patients and is expected to generate top-line data in 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top